Georges Tabary will help the optical imaging company meet the strong demands of the market
Paris, France, March 14, 2016 - BioAxial, a key player in live cell super resolution microscopy, today announces the appointment of Georges Tabary as its president and chief executive officer.
BioAxial develops imaging instruments for fluorescence microscopy that allow extended imaging of live cells with a very high resolution, thus far difficult to reach in research laboratories. This innovative module allows observation of living cells, without damaging them; unlike most of its competitors, Bioaxial technology also does not require complex manipulations.
In 2013 the company received funding from Amorçage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and ACG Management (formerly Viveris Management).
“We are thrilled to welcome Georges to this key leadership position,” said Frank Lison, PhD, chairman of BioAxial. “He has a proven track record developing new businesses and leading sales and marketing strategy for pioneering and highly advanced life science technology companies, such as Leica Microsystems, Intuitive Surgical, Technomed International, ELA Medical and Mauna Kea.”
“We are enthusiastic about Georges joining; with his outstanding experience he will bring strategic leadership and market knowledge,” said Gabriel Sirat and Louis-Philippe Braitbart, co-founders of BioAxial. “His deep understanding of business needs will be instrumental in taking our company to the next level and we are determined to give him our full support and commitment to succeed as a team.”
“I am delighted to be joining the BioAxial team,” said Georges Tabary. “The super-resolution microscopy industry is today one of the fastest growing, supported by strong demand from life science companies. Microscopy is a key tool in the life science industry as it helps to accelerate research by combining scientific knowledge and technological know-how.”
The global microscopy market is poised to reach $5.76bn (€5.15bn) by 2019 from $4.07bn (€3.63bn) in 2014, at a CAGR of 7.2% from 2014 to 2019. [1]
Tabary comes to BioAxial from Mauna Kea Technologies, where he was vice president of strategic accounts; prior to this he spent seven years with Leica Microsystems (Danaher Group), leading the company’s European surgical microscopy and histopathology businesses, overseeing strong growth in both areas. He was also president of Leica Microsystèmes SAS (France).
Prior to Leica, Tabary served as vice president and general manager for Intuitive Surgical Europe. He also spent nine years in Japan, where he was managing director for Technomed and healthcare business general manager Northern Asia for Air Liquide.
About BioAxial
BioAxial develops and sells CODIM, a new technology for super-resolved fluorescence microscopy for extended imaging of live cells with a resolution in the range of 100nm. The modules manufactured by BioAxial can be adapted as an add-on for commercial microscopes.
BioAxial, founded in 2010, has its headquarters in Paris. It was founded by Gabriel Sirat and Louis-Philippe Braitbart, who both trained as physicists and have international careers in the semi-conductor and optical metrology industries.
BioAxial raised €1.9m ($2.1m) in 2013 with three large investors – Amorçage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and ACG Management (formerly Viveris Management), plus a range of individual investors.
www.bioaxial.com
About CEA Investissement
CEA Investissement, a subsidiary of the CEA, is a specialist in seed investment in technology companies. Its proximity to public research laboratories and the venture capital industry has made it a key player in launching and financing startup companies in France. To date, it has funded over 50 companies and currently has €110m ($123m) under management. With 15 years experience in seed investment, CEA Investissement has generated several successful exits, including companies such as TRACIT, ULIS, MOVEA and FERMENTALG. The investment in BioAxial was made through the Amorçage Technologique Investissement (ATI) fund, managed by CEA Investissement. The CEA, BPI (using the FNA), EDF, SAFRAN and BIOMERIEUX are investors in ATI.
http://www.cea-investissement.com
About Inserm Transfert Initiative
Inserm Transfert Initiative (ITI) is a French investment fund dedicated to early-stage life science companies. Since 2001, ITI has backed over 25 start-up companies in the healthcare sector and developed strong connections with public and private partners in France and around the world. This strong partnership, alongside ITI’s experienced team, offers durable support to management teams of portfolio companies throughout their development. To date, ITI has approx. €40 million ($44.7m) of funds under management dedicated to seed investment in life sciences. It has an office in Paris, France. www.it-initiative.fr About ACG Management ACG Management is an independent French private equity firm dedicated to unlisted small-cap asset management strategies. Founded in 2000 and located in Marseille, it focuses on SMEs mostly located in France, in the Overseas French territories and across the Mediterranean, with expertise in all strategies (buy-out, venture capital and growth capital).
Combining independence, product innovation and hands-on management, ACG Management has so far raised or advised on over €780m ($872m) worth of assets and invested in 316 SMEs through a wide range of 60 investment vehicles including retail and institutional funds.
Relying on a team of 37 experienced professionals spread out across our different offices in Paris, Marseille, Corsica and Saint-Denis, Reunion Island, it accounts for over 40.000 private individual or institutional investors.
